Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Clinical Trial 14026

Houston, TX 77074


Study summary:

In this randomized, double-blind, double dummy parallel group trial, the efficacy and safety of once daily oral administration of the fixed dose combination (FDC) of linagliptin/pioglitazone will be investigated in type 2 diabetic patients with insufficient glycaemic control.


Qualified Participants Must:

• Have a diagnosis of type 2 diabetes mellitus prior to informed consent
• Have insufficient glycaemic control (HbA1c ≥ 7.0 to≤ 10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within 10 weeks prior to start of the run-in period (date of Visit 2)
• Be 18-80 years of age at start date of Visit 1 (Screening)
• Have BMI ≤ 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)


Qualified Participants to Receive:

Stipend for participation and time.


Research Site Profile

View Clinic Profile